'Treatment uptake' diaporamas de présentation

Treatment of HCV infection among active IDUs

Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research University of New South Wales. Treatment of HCV infection among active IDUs. Hepatitis C treatment. Sustained virologic response. ?. PEG-IFN+RBV

395 views • 26 slides

Treatment of HCV infection among active IDUs

Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research University of New South Wales. Treatment of HCV infection among active IDUs. Hepatitis C treatment. Sustained virologic response. ?. PEG-IFN+RBV

370 views • 26 slides

Treatment of HCV infection among active IDUs

Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research University of New South Wales. Treatment of HCV infection among active IDUs. Hepatitis C treatment. Sustained virologic response. ?. PEG-IFN+RBV

350 views • 26 slides

Hepatitis C: Overview and Epidemiology

Hepatitis C: Overview and Epidemiology. Heidar Sharafi, PhDc. Baqiyatallah Research Center for Gastroenterology and Liver Disease (BRCGL). Hepatitis C Virus. Natural History of Hepatitis C. Exposure. Acute or Early Phase. Chronic HCV 65-80%. Resolved 20-35%. Cirrhosis 5-25%.

381 views • 22 slides

HCV Infection in Marginalized Populations

HCV Infection in Marginalized Populations. Brian Conway, MD, FRCPC Vancouver Infectious Diseases Centre (VIDC). IDUs will drive the future HCV epidemic in Canada. 300,000 HCV-infected Canadians, including over 180,000 IDUs (60% of prevalent cases)

325 views • 19 slides

279 views • 15 slides

Improving Decision-Making for Medications in Rheumatoid Arthritis

Improving Decision-Making for Medications in Rheumatoid Arthritis. Edward Yelin , Ph.D. Jennifer Barton, M.D. Laura Trupin , M.P.H. Gina Evans-Young University of California, San Francisco.

188 views • 8 slides